Sex disparities in mortality and cardiovascular outcomes in chronic kidney disease
Clinical Kidney Journal · 01.03.2024 · 17 (3)
DOI: 10.1093/ckj/sfae044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 21.02.2024. Verfasst von Olga Balafa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University Hospital of Ioannina, Ioannina, Greece. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FEDER, Instituto de Salud Carlos III, European Cooperation in Science and Technology.
Abstract (Originalsprache)
Sex (biologically determined) and gender (socially constructed) modulate manifestations and prognosis of a vast number of diseases, including cardiovascular disease (CVD) and chronic kidney disease (CKD). CVD remains the leading cause of death in CKD patients. Population-based studies indicate that women present a higher prevalence of CKD and experience less CVD than men in all CKD stages, although this is not as clear in patients on dialysis or transplantation. When compared to the general population of the same sex, CKD has a more negative impact on women on kidney replacement therapy. European women on dialysis or recipients of kidney transplants have life expectancy up to 44.8 and 19.8 years lower, respectively, than their counterparts of similar age in the general population. For men, these figures stand at 37.1 and 16.5 years, representing a 21% to 20% difference, respectively. Hormonal, genetic, societal, and cultural influences may contribute to these sex-based disparities. To gain a more comprehensive understanding of these differences and their implications for patient care, well-designed clinical trials that involve a larger representation of women and focus on sex-related variables are urgently needed. This narrative review emphasizes the importance of acknowledging the epidemiology and prognosis of sex disparities in CVD among CKD patients. Such insights can guide research into the underlying pathophysiological mechanisms, leading to optimized treatment strategies and ultimately, improved clinical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, University Hospital of Ioannina, Ioannina, Greece.
- Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.
- Nephrology Dept, Faculty of Medicine, University of Ioannina and University Hospital of Ioannina. Ioannina, Greece.
- Department of Dialysis, Clinic for Internal Medicine, Faculty of Medicine, University Medical Centre Maribor, Maribor, Slovenia.
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
ORCID-Profile: Olga Balafa, Beatriz Fernandez-Fernandez, Alberto Ortiz, Charles J Ferro, Patrick B Mark
Förderung
- FEDER
- Instituto de Salud Carlos III
- European Cooperation in Science and Technology
Zitieren
APA
Balafa, O., Fernandez-Fernandez, B., Ortiz, A., Dounousi, E., Ekart, R., Ferro, C. J., Mark, P. B., Valdivielso, J. M., Del Vecchio, L., & Mallamaci, F. (2024). Sex disparities in mortality and cardiovascular outcomes in chronic kidney disease. Clinical Kidney Journal, 17(3). https://doi.org/10.1093/ckj/sfae044
Vancouver
Balafa O, Fernandez-Fernandez B, Ortiz A, Dounousi E, Ekart R, Ferro CJ, et al. Sex disparities in mortality and cardiovascular outcomes in chronic kidney disease. Clinical Kidney Journal. 2024;17(3). doi:10.1093/ckj/sfae044
BibTeX
@article{Balafa2024,
author = {Balafa, Olga and Fernandez-Fernandez, Beatriz and Ortiz, Alberto and Dounousi, Evangelia and Ekart, Robert and Ferro, Charles J and Mark, Patrick B and Valdivielso, Jose M and Del Vecchio, Lucia and Mallamaci, Francesca},
title = {Sex disparities in mortality and cardiovascular outcomes in chronic kidney disease},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {3},
doi = {10.1093/ckj/sfae044}
}
EUVIMED